Fernández Erlinda, Toledo Jorge R, Mansur Manuel, Sánchez Oliberto, Gil Dayrom F, González-González Yamile, Lamazares Emilio, Fernández Yaiza, Parra Francisco, Farnós Omar
Animal Biotechnology Division, Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, 10600, Havana, Cuba.
Appl Microbiol Biotechnol. 2015 May;99(9):3875-86. doi: 10.1007/s00253-014-6171-z. Epub 2014 Nov 18.
The yeast Pichia pastoris is one of the most robust cell factories in use for the large-scale production of biopharmaceuticals with applications in the fields of human and animal health. Recently, intracellular high-level expression of rabbit hemorrhagic disease virus (RHDV) capsid protein (VP1) as a self-assembled multipurpose antigen/carrier was established as a production process from P. pastoris. Since recovery of VP1 from the culture media implies technological and economic advantages, the secretion of VP1 variants was undertaken in this work. Conversely, extensive degradation of VP1 was detected. Variations to culture parameters and supplementation with different classes of additives were unable to diminish degradation. Strategies were then conducted during fermentations using a recombinant variant of a non-specific BPTI-Kunitz-type protease inhibitor (rShPI-1A) isolated from the sea anemone Stichodactyla helianthus. The presence of the inhibitor in the culture medium at the recombinant protein induction phase, as well as co-culture of the yeast strains expressing VP1 and rShPI-1A, led to VP1 protection from proteolysis and to production of ordered virus-like particles. A yeast strain was also engineered to co-express the rShPI-1A inhibitor and intact VP1. Expression levels up to 116 mg L(-1) of VP1 were reached under these approaches. The antigen was characterized and purified in a single chromatography step, its immunogenic capacity was evaluated, and a detection test for specific antibodies was developed. This work provides feasible strategies for improvements in P. pastoris heterologous protein secretion and is the first report on co-expression of the ShPI-1A with a recombinant product otherwise subjected to proteolytic degradation.
巴斯德毕赤酵母是用于大规模生产生物制药的最强大的细胞工厂之一,在人类和动物健康领域有应用。最近,在巴斯德毕赤酵母中建立了细胞内高水平表达兔出血性疾病病毒(RHDV)衣壳蛋白(VP1)作为自组装多功能抗原/载体的生产工艺。由于从培养基中回收VP1具有技术和经济优势,因此本研究进行了VP1变体的分泌研究。然而,检测到VP1发生了广泛降解。改变培养参数和添加不同类别的添加剂均无法减少降解。随后在发酵过程中采用了从海葵日光海葵中分离出的非特异性BPTI-库尼茨型蛋白酶抑制剂(rShPI-1A)的重组变体。在重组蛋白诱导阶段,培养基中存在该抑制剂,以及表达VP1和rShPI-1A的酵母菌株共培养,均导致VP1免受蛋白水解,并产生有序的病毒样颗粒。还构建了一种酵母菌株,使其共表达rShPI-1A抑制剂和完整的VP1。在这些方法下,VP1的表达水平达到了116 mg L(-1)。对该抗原进行了表征,并通过一步色谱法进行了纯化,评估了其免疫原性,并开发了特异性抗体检测试验。这项工作为改进巴斯德毕赤酵母异源蛋白分泌提供了可行策略,并且是关于ShPI-1A与其他易受蛋白水解降解的重组产物共表达的首次报道。